Literature DB >> 25023322

High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.

Larysa Alekseychyk1, Cheng Su2, Gerald W Becker1, Michael J Treuheit1, Vladimir I Razinkov3.   

Abstract

Selection of a suitable formulation that provides adequate product stability is an important aspect of the development of biopharmaceutical products. Stability of proteins includes not only resistance to chemical modifications but also conformational and colloidal stabilities. While chemical degradation of antibodies is relatively easy to detect and control, propensity for conformational changes and/or aggregation during manufacturing or long-term storage is difficult to predict. In many cases, the formulation factors that increase one type of stability may significantly decrease another type under the same or different conditions. Often compromise is necessary to minimize the adverse effects of an antibody formulation by careful optimization of multiple factors responsible for overall stability. In this study, high-throughput stress and characterization techniques were applied to 96 formulations of anti-streptavidin antibodies (an IgG1 and an IgG2) to choose optimal formulations. Stress and analytical methods applied in this study were 96-well plate based using an automated liquid handling system to prepare the different formulations and sample plates. Aggregation and clipping propensity were evaluated by temperature and mechanical stresses. Multivariate regression analysis of high-throughput data was performed to find statistically significant formulation factors that alter measured parameters such as monomer percentage or unfolding temperature. The results of the regression models were used to maximize the stabilities of antibodies under different formulations and to find the optimal formulation space for each molecule. Comparison of the IgG1 and IgG2 data indicated an overall greater stability of the IgG1 molecule under the conditions studied. The described method can easily be applied to both initial preformulation screening and late-stage formulation development of biopharmaceutical products.
© 2014 Society for Laboratory Automation and Screening.

Entities:  

Keywords:  aggregation propensity; biopharmaceuticals; design of experiment; drug development; formulation screening; high-throughput method; manufacturability; protein characterization

Mesh:

Substances:

Year:  2014        PMID: 25023322     DOI: 10.1177/1087057114542431

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  3 in total

1.  Toward Biotherapeutics Formulation Composition Engineering using Site-Identification by Ligand Competitive Saturation (SILCS).

Authors:  Sandeep Somani; Sunhwan Jo; Renuka Thirumangalathu; Danika Rodrigues; Laura M Tanenbaum; Ketan Amin; Alexander D MacKerell; Santosh V Thakkar
Journal:  J Pharm Sci       Date:  2020-11-01       Impact factor: 3.784

2.  Evaluation of Crystal Zenith Microtiter Plates for High-Throughput Formulation Screening.

Authors:  J Alaina Floyd; Jeremy M Shaver; Alison J Gillespie; Unjy Park; Richard S Rogers; Nancy S Nightlinger; Yuko Ogata; Jeffrey J James; Bruce A Kerwin
Journal:  J Pharm Sci       Date:  2019-10-25       Impact factor: 3.534

3.  Molecular computations of preferential interactions of proline, arginine.HCl, and NaCl with IgG1 antibodies and their impact on aggregation and viscosity.

Authors:  Theresa K Cloutier; Chaitanya Sudrik; Neil Mody; Sathish A Hasige; Bernhardt L Trout
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.